Aim: There is growing interest in pharmacologic ascorbate (Asc) and its therapeutic properties (Levine et al. Adv Nutr 2011;2:78). W e examined cell viability, histone deacetylase (HDAC) expression, and related protein modifications in cancer versus non- cancer colon epithelial cells following exposure to Asc.
Methods: MTT assays were conducted in...
Full Text:
248.3
An epigenetic perspective on pharmacologic ascorbate in
colon cancer
Matthew Carl Kaiser1
Aim: There is growing interest in pharmacologic ascorbate (Asc) and its therapeutic properties (Levine et al. Adv Nutr 2011;2:78). W e examined cell viability, histone deacetylase (HDAC) expression, and related protein modifications in cancer versus non- cancer colon epithelial cells following exposure to Asc.
Methods: MTT assays were conducted in...
Full Text:
An Epigenetic Perspective on
Pharmacologic Ascorbate in
Aim: There is growing interest in pharmacologic ascorbate (Asc) and its therapeutic properties (Levine et al. Adv Nutr 2011;2:78). W e examined cell viability, histone deacetylase (HDAC) expression, and related protein modifications in cancer versus non- cancer colon epithelial cells following exposure to Asc.
Methods: MTT assays were conducted in...
Full Text:
Agent in Colon Cancer
An Epigenetic Perspective on
Pharmacologic Ascorbate in Colon Cancer
Matthew
Aim: There is growing interest in pharmacologic ascorbate (Asc) and its therapeutic properties (Levine et al. Adv Nutr 2011;2:78). W e examined cell viability, histone deacetylase (HDAC) expression, and related protein modifications in cancer versus non- cancer colon epithelial cells following exposure to Asc.
Methods: MTT assays were conducted in...